The latest update is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals has announced the receipt of a filing notice from the China Securities Regulatory Commission (CSRC) regarding the full circulation of its H shares. This development allows for the conversion of 14,114,006 unlisted shares into H shares, which will be listed on the Hong Kong Stock Exchange. The move is expected to enhance the liquidity of the company’s shares and potentially improve its market position.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a joint stock company incorporated in China, focusing on the biopharmaceutical industry. The company is involved in the development of innovative cancer immunotherapies and related biopharmaceutical products.
YTD Price Performance: -5.62%
Average Trading Volume: 9,194,431
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$2.03B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.